Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025

Reuters2025-10-28

Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025

Acurx Pharmaceuticals Inc. has announced new data on its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready candidate ibezapolstat. The results were presented at the Infectious Diseases Society of America $(IDSA)$ IDWeek 2025 Scientific Conference. The presentation included updates on ibezapolstat's selective antibacterial activity in the gut, which spares beneficial bile acid-metabolizing bacteria and may contribute to reduced recurrence of C. difficile infection. Additionally, new colonic microbiome data from a mouse infection model suggest that microbiome selectivity may be a class effect among DNA pol IIIC inhibitors, when compared to the comparator antibiotic linezolid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06296) on October 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2578959307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578959307","market":"fut","top_or_hot":-1,"title":"Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acurx Pharmaceuticals Inc. has announced new data on its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready candidate ibezapolstat. The results were presented at the Infectious Diseases Society of America <a href=\"https://laohu8.com/S/IDSA\">$(IDSA)$</a> IDWeek 2025 Scientific Conference. The presentation included updates on ibezapolstat's selective antibacterial activity in the gut, which spares beneficial bile acid-metabolizing bacteria and may contribute to reduced recurrence of C. difficile infection. Additionally, new colonic microbiome data from a mouse infection model suggest that microbiome selectivity may be a class effect among DNA pol IIIC inhibitors, when compared to the comparator antibiotic linezolid.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06296) on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-28 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acurx Pharmaceuticals Inc. has announced new data on its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready candidate ibezapolstat. The results were presented at the Infectious Diseases Society of America <a href=\"https://laohu8.com/S/IDSA\">$(IDSA)$</a> IDWeek 2025 Scientific Conference. The presentation included updates on ibezapolstat's selective antibacterial activity in the gut, which spares beneficial bile acid-metabolizing bacteria and may contribute to reduced recurrence of C. difficile infection. Additionally, new colonic microbiome data from a mouse infection model suggest that microbiome selectivity may be a class effect among DNA pol IIIC inhibitors, when compared to the comparator antibiotic linezolid.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06296) on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL9Xmndj:1","article_id":"2578959307","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578959307","pubTimestamp":1761653018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acurx Pharmaceuticals Inc. has announced new data on its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready candidate ibezapolstat. The results were presented at the Infectious Diseases Society of America  IDWeek 2025 Scientific Conference. The presentation included updates on ibezapolstat's selective antibacterial activity in the gut, which spares beneficial bile acid-metabolizing bacteria and may contribute to reduced recurrence of C. difficile infection. Additionally, new colonic microbiome data from a mouse infection model suggest that microbiome selectivity may be a class effect among DNA pol IIIC inhibitors, when compared to the comparator antibiotic linezolid.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ACXP":"Acurx Pharmaceuticals, LLC*","BK4139":"生物科技","BK4563":"昨日强势股"},"translate_title":"Acurx Pharmaceuticals在IDWeek 2025上公布了有关微生物保护抗生素Ibezapolstat的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACXP":0.9},"content_text":"Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025\n    \n\n        Acurx Pharmaceuticals Inc. has announced new data on its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready candidate ibezapolstat. The results were presented at the Infectious Diseases Society of America $(IDSA)$ IDWeek 2025 Scientific Conference. The presentation included updates on ibezapolstat's selective antibacterial activity in the gut, which spares beneficial bile acid-metabolizing bacteria and may contribute to reduced recurrence of C. difficile infection. Additionally, new colonic microbiome data from a mouse infection model suggest that microbiome selectivity may be a class effect among DNA pol IIIC inhibitors, when compared to the comparator antibiotic linezolid.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06296) on October 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578959307","isCrawlerRequest":true}